| abstract |
Novel crystalline forms of a spiro compound that acts as a muscarinic acetylcholine receptor agonist are provided. In particular, isolated crystalline polymorphic forms of (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4,5]decan-3-one are described which have favorable properties in pharmaceutical manufacturing. Also provided are methods of preparing said crystalline polymorphs and converting them into one another, as well as methods of preparing medicaments containing them, which are suitable for use in the treatment of diseases and disorders responsive to modulation of the muscarinic acetylcholine receptor. . |